2018

Decreased mortality of pulmonary arterial hypertension in Duchenne muscular dystrophy and Down syndrome

Mitchell Volin
University of North Dakota

Follow this and additional works at: https://commons.und.edu/pas-grad-posters
Part of the Pulmonology Commons

Recommended Citation
https://commons.und.edu/pas-grad-posters/28

This Poster is brought to you for free and open access by the Department of Physician Studies at UND Scholarly Commons. It has been accepted for inclusion in Physician Assistant Scholarly Project Posters by an authorized administrator of UND Scholarly Commons. For more information, please contact zeinebyousif@library.und.edu.
The Pulmonary Hypertension Association summarized the NCBI. PH with slight limitation 52 21 56 double or triple BMPR2 epistatic PubMed Individuals that do not demonstrate a vasoreactive Ambrisentan & tadalafil Supportive therapy and general measures with expert

earlier diagnosis of and screening for PAH (Tonelli et al., 2013). Both of these disorders have high mortality rates. Research has led to PAH is a growing concern (Peacock, Murphy, 
Recent studies have provided insight in the diagnosis and screening for both familial and associated pulmonary arterial hypertension. Research has led to earlier diagnosis of and screening for PAH (Tonelli et al., 2013).

Unfortunately, co-morbid and/or exacerbating conditions often dictate patient outcome (Tonelli et al., 2013). Many disorders of the body cause APAH. Two genetic conditions having co-morbid occurrence of APAH are Down syndrome and Duchenne muscular dystrophy. Both of these disorders have high mortality rates.